Weight loss drugs like Ozempic deliver more health benefits than expected.

Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Diabetes is a leading cause of chronic kidney disease (CKD) worldwide, and with about 4.2 million South Africans living with diabetes, raising awareness is essential. About 40% of ...

Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and management of chronic kidney disease (CKD) in adults and children.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...